is glp 1 safe while pregnant Study finds no major early pregnancy risks tied to GLP-1 drugs, but doctors still advise against use GLP-1s (Weight loss injections) AND

The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications

Learn how LifeRx.md's approach tackles obesity and reduces cardiovascular risks effectively.

It plays a key role in regulating GLP-1 production, helping to control appetite and support natural weight management

Bridging the gap between clinical potential and real-world impact enables stakeholders to decode the complex interplay of these forces and rethink what it truly takes to keep patients on the path to sustained outcomes

These real-world GLP-1 eating tips cover nausea foods, soft protein, timing, and shot-day meals.